U.S., June 14 -- ClinicalTrials.gov registry received information related to the study (NCT07021209) titled 'Clinical Study of GT719 Injection for Recurrent/Refractory Antibody Mediated Systemic Immune Diseases' on May 29.
Brief Summary: This study is an open-label, prospective, exploratory clinical trial that includes a dose escalation phase and a dose expansion phase, aimed at evaluating the safety, cell dynamics, and preliminary efficacy of GT719 cells in adult participants with recurrent/refractory antibody-mediated neurological immune disorders.
Study Start Date: Jan. 14
Study Type: INTERVENTIONAL
Condition:
Neurological Disorder
Intervention:
BIOLOGICAL: GT719 Injection
GT719 Injection
Recruitment Status: RECRUITING
Sponsor:...